Filing Details
- Accession Number:
- 0001209191-21-063200
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2021-11-05 17:00:21
- Reporting Period:
- 2021-11-04
- Accepted Time:
- 2021-11-05 17:00:21
- SEC Url:
- Form 4 Filing
Issuer
| Cik | Name | Symbol | Sector (SIC) | IRS No |
|---|---|---|---|---|
| 1492426 | Horizon Therapeutics Public Ltd Co | HZNP | Pharmaceutical Preparations (2834) | 000000000 |
Insiders
| Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
|---|---|---|---|---|---|---|---|
| 1619500 | Barry Moze | C/O Horizon Therapeutics Plc, 70 Saint Stephen?S Green Dublin L2 D02 E2X4 | Evp, Chief Admin. Officer | No | Yes | No | No |
Reported Non-Derivative Transactions
| Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|---|---|---|---|---|---|
| Ordinary Shares | Acquisiton | 2021-11-04 | 3,000 | $22.14 | 78,681 | No | 4 | M | Direct | |
| Ordinary Shares | Acquisiton | 2021-11-04 | 443 | $11.81 | 79,124 | No | 4 | M | Direct | |
| Ordinary Shares | Acquisiton | 2021-11-04 | 72,300 | $14.48 | 151,424 | No | 4 | M | Direct | |
| Ordinary Shares | Disposition | 2021-11-04 | 23,382 | $110.17 | 128,042 | No | 4 | S | Direct | |
| Ordinary Shares | Disposition | 2021-11-04 | 15,856 | $111.75 | 112,186 | No | 4 | S | Direct | |
| Ordinary Shares | Disposition | 2021-11-04 | 6,151 | $112.60 | 106,035 | No | 4 | S | Direct | |
| Ordinary Shares | Disposition | 2021-11-04 | 17,867 | $113.56 | 88,168 | No | 4 | S | Direct | |
| Ordinary Shares | Disposition | 2021-11-04 | 6,763 | $114.43 | 81,405 | No | 4 | S | Direct | |
| Ordinary Shares | Disposition | 2021-11-04 | 5,724 | $115.45 | 75,681 | No | 4 | S | Direct |
| Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|
| No | 4 | M | Direct | |
| No | 4 | M | Direct | |
| No | 4 | M | Direct | |
| No | 4 | S | Direct | |
| No | 4 | S | Direct | |
| No | 4 | S | Direct | |
| No | 4 | S | Direct | |
| No | 4 | S | Direct | |
| No | 4 | S | Direct |
Reported Derivative Transactions
| Sec. Name | Sec. Type | Acquisiton - Disposition | Date | Amount | Price | Amount - 2 | Price - 2 |
|---|---|---|---|---|---|---|---|
| Ordinary Shares | Stock Option (Right to Buy) | Disposition | 2021-11-04 | 3,000 | $0.00 | 3,000 | $22.14 |
| Ordinary Shares | Stock Option (Right to Buy) | Disposition | 2021-11-04 | 443 | $0.00 | 443 | $11.81 |
| Ordinary Shares | Stock Option (Right to Buy) | Disposition | 2021-11-04 | 72,300 | $0.00 | 72,300 | $14.48 |
| Remaning Holdings | Exercise Date | Expiration Date | Equity Swap Involved | Transaction Form Type | Transaction Code | Nature of Ownership |
|---|---|---|---|---|---|---|
| 162,181 | 2025-03-22 | No | 4 | M | Direct | |
| 0 | 2024-09-11 | No | 4 | M | Direct | |
| 0 | 2024-06-05 | No | 4 | M | Direct |
Footnotes
- The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 14, 2021.
- The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $110.00 to $110.985 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
- The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $111.10 to $112.07 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
- The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $112.12 to $113.085 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
- The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $113.14 to $114.135 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
- The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $114.14 to $115.12 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
- The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $115.15 to $115.88 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
- The stock option is fully vested and exercisable.
Billionaire Hedge Funds
